Promising liver cancer combo trial halted early – only 4 patients enrolled
NCT ID NCT06332079
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 study tested a two-step treatment for colorectal cancer that had spread only to the liver and could not be removed by surgery. First, patients received radioactive beads (Holmium-166 TARE) directly into the liver, followed by maintenance chemotherapy and targeted drugs. The goal was to see how long the cancer stayed under control. However, the trial was terminated early after enrolling only 4 participants, so no firm conclusions can be drawn.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Holmium-166 TARE (a radioactive procedure targeting liver tumors), combined with chemotherapy (fluoropyrimidine) and targeted agents (cetuximab, panitumumab, or bevacizumab)
- What this could lead to
- If successful, this approach could offer a way to control liver tumors in colorectal cancer patients who cannot have surgery, potentially delaying disease progression.
- What could go wrong
- The trial was terminated early with only 4 participants, so results are very limited. The combination of radiation and chemotherapy carries risks of liver damage and other side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Azienda Ospedaliero Universitaria Pisana
Pisa, 56126, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug combo shrink Hard-to-Treat tumors?
- Can a smart drug home in on Hard-to-Treat cancers?
- Can a vaccine boost immunotherapy against a stubborn cancer?
- Can a new immunotherapy combo shrink Hard-to-Treat tumors?
- What does recovery really look like after aggressive peritoneal cancer surgery?
- Chemo holidays put to the test: can scheduled breaks beat continuous treatment for advanced colorectal cancer?